Related Experiment Video
Updated: May 31, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.
1Department of Neurology, Hospital de São João, Porto, Portugal. mendes.amelia@gmail.com
Arquivos De Neuro-Psiquiatria
|July 15, 2011
Summary
Interferon beta (IFNβ) and glatiramer acetate (GA) are established treatments for multiple sclerosis (MS). These immunomodulators effectively reduce relapses and lesions, offering a good safety profile despite unclear precise mechanisms.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Interferon beta (IFNβ) and glatiramer acetate (GA) were the first immunomodulators approved for relapsing-remitting multiple sclerosis (MS).
- Despite new therapies, IFNβ and GA remain widely used and are considered the therapeutic mainstay for MS.
Purpose of the Study:
- To review the mechanisms of action of IFNβ and GA in MS.
- To summarize the main clinical results associated with these treatments.
Main Methods:
- Review of existing literature on IFNβ and GA mechanisms and clinical outcomes in MS.
- Analysis of clinical trial data regarding efficacy and safety.
Main Results:
- IFNβ modulates T and B-cell activity and affects the blood-brain barrier.
- GA induces immune deviation by promoting anti-inflammatory cytokine expression.
- Both agents demonstrated a 30% reduction in annualized relapse rate and T2 lesions on MRI, with potential neuroprotective roles.
Conclusions:
- IFNβ and GA have recognized beneficial effects in MS treatment, supported by good safety and tolerability profiles.
- Extensive clinical experience over two decades supports their use.
- These established therapies provide a benchmark for newer, potentially less safe, agents, aiding individualized treatment selection.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.